Recruitment begins for world’s first ovarian cancer vaccine trial

Patients are now being recruited for the world’s first personalised genomics-driven ovarian cancer vaccine clinical trial. The goal is to prevent an often deadly relapse of the disease in women diagnosed at advanced stages.

The injectable vaccine OncoImmunome works by boosting the patient’s immune response to enable it to destroy ovarian cancer cells should they resurface.

The FDA approved the human clinical trial testing of the experimental vaccine therapy following published research findings showing its effectiveness in reducing cancer growth in animal models.

The new clinical trial will begin with the enrollment of 15 women with stage III or IV ovarian cancer at initial diagnosis or first relapse.

Clinical trial candidates are women diagnosed with advanced stage III or IV ovarian cancer who will have traditional surgery where tumour samples will be collected for vaccine production, followed by standard chemotherapy.

If cancer-free after traditional treatment, the women will each receive their personalised vaccine injections once a month for six months. Each ovarian cancer vaccine is individually created for each woman using her own DNA.

Read more:

https://medicalxpress.com/news/2017-04-world-ovarian-cancer-vaccine-trial.html

https://clinicaltrials.gov/ct2/show/NCT02933073?term=ovarian+uconn+health&rank=1

Image credit: https://medicalxpress.com/news/2017-04-world-ovarian-cancer-vaccine-trial.html

Κράτα το

cancer cells DNA ovarian cancer relapse toumor vaccine